Previous 10 | Next 10 |
Markets have settled and recovered from the initial shock of the coronavirus spread and the response of governments around the US and the world to lock down the economy. But while the major US indices have approached, if not quite matched, the fabled v-shaped recovery, there are still plenty o...
Are These Biotech Penny Stocks On Your List Right Now? One of the hottest sectors this year is biotechnology. No matter if you like momentum, speculation, fundamentals, etc. there are plenty of biotech penny stocks to watch in 2020. With that, it’s important to understand some of the ...
Minerva Neurosciences (NASDAQ: NERV) , a small-cap biotech, is rebounding a bit Monday after a dramatic plunge on Friday. Specifically, the drugmaker's shares are up by 16.4% as of 12:47 p.m. EDT. Minerva's shares cratered by 72.5% on Friday in response to the late-stage failu...
Are The On Your List Of Penny Stocks Right Now? We’re heading into the first week of June and penny stocks couldn’t be any hotter. The riots over the weekend and continued increase of coronavirus cases have a number of stocks taking off on Monday. The biggest question now is wh...
Digital Ally (NASDAQ: DGLY ) +81% as Body-camera, surveillance stocks surge pre-market after protests . More news on: Digital Ally, Inc., Allied Esports Entertainment Inc., CTI BioPharma Corp., Stocks on the move, , Read more ...
WALTHAM, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the company will hold a webcast on Friday, June 5, 20...
These Penny Stocks Just Hit New 52-Week Highs. Are They Still A Buy? There’s no getting around the fact that penny stocks are high-risk equities. Just as quickly as they move up, they can come crashing down. In line with this, there’ve been plenty of higher-priced stocks that r...
Shares of Minerva Neurosciences (NASDAQ: NERV) fell by as much as 86% Friday after the company reported disappointing late-stage results for its lead drug candidate. In a phase 3 trial, roluperidone proved statistically no better than a placebo in treating negative symptoms of schizophrenia....
Gainers: Sonoma Pharmaceuticals (NASDAQ: SNOA ) +145% . More news on: Sonoma Pharmaceuticals, Inc., Adaptimmune Therapeutics plc, Phio Pharmaceuticals Corp., Stocks on the move, , Read more ...
Minerva Neurosciences tanks ( NERV -81.4% ) after the company announces disappointing results from Phase 3 clinical trial evaluating roluperidone (MIN-101) in adults with negative symptoms of schizophrenia More news on: Minerva Neurosciences, Inc., Healthcare stocks news, Stocks on t...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...